Skip to Content
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees

The $136.8 billion revenue drug wholesaler and medical supplier managed 5.3% sales growth in 2018 despite an increasingly challenging environment largely due to greater sales of high-price drugs used in oncology, among other medical specialties. The bulk of Cardinal’s revenue comes from the medications it distributes to pharmacies and is impacted by fluctuations in drug prices. The declining price of generics has weighed on the company’s bottom line in recent years and the heightened scrutiny of drug pricing has created uncertainty for Cardinal and its two bigger rivals, McKesson and AmerisourceBergen. The industry is also under continued pressure—and faces a growing number of lawsuits—over its alleged role in the nation’s opioid epidemic.

Company Info

Figures are for fiscal year ended June 30, 2018.
Michael C. Kaufmann
CEO Title
Chairman & Chief Executive Officer
Health Care
Wholesalers: Health Care
HQ Location
Dublin, Ohio
Years on Fortune 500 List25
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Cardinal Health Rank History


Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$136,809.05.3%
Profits ($M)$256.0-80.1%
Assets ($M)$39,951.0-
Total Stockholder Equity ($M)$6,059.0-

Profit Ratios

Profit as % of Revenues0.2%
Profits as % of Assets0.6%
Profits as % of Stockholder Equity4.2%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)0.81
EPS % Change (from 2017)-79.9%
EPS % Change (5 year annual rate)-3.5%
EPS % Change (10 year annual rate)-13.8%

Total Return

Total Return to Investors (2018)-24.8%
Total Return to Investors (5 year, annualized)-5.6%
Total Return to Investors (10 year, annualized)8.4%